ASCO Launches Online Educational Initiative: ‘Grand Rounds’

Publication
Article
OncologyONCOLOGY Vol 14 No 7
Volume 14
Issue 7

The American Society of Clinical Oncology (ASCO) recently launched a new online education resource-ASCO Grand Rounds- for cancer professionals, featuring biweekly CME-accredited lectures on current topics in cancer. The lectures will

The American Society of Clinical Oncology (ASCO) recently launched a new online education resource—ASCO Grand Rounds— for cancer professionals, featuring biweekly CME-accredited lectures on current topics in cancer. The lectures will be conducted by leading oncologists and cancer-care professionals and will include a physician-moderated online question-and-answer session for ASCO members. This new resource is available from ASCO OnLine, at www.asco.org.

Staying Current

ASCO Grand Rounds offers physicians an easy way to stay abreast of developments in cancer research. Each lecture consists of a 20- to 45-minute discussion that participants can listen to while viewing a synchronized slide presentation. Lectures will cover topics such as new drug development, cancer genetics, and supportive care and will be available throughout the year on ASCO’s website. Approximately two new lectures will be presented each month.

“We are excited that ASCO is taking a leading role in providing online education to oncologists around the world,” said ASCO president Joseph S. Bailes, MD.

Articles in this issue
Non–Small-Cell Lung Cancer Single-Agent Therapy
Linezolid-A New Option for Treating Gram-Positive Infections
Current Issues in the Treatment of Resistant Bloodstream Infections
Current Treatments for Infection in Neutropenic Patients With Hematologic Malignancy
Changing Patterns of Infections and Antimicrobial Susceptibilities
Ambulatory Antimicrobial Therapy for Hematologic Malignancies
Questions and Answers: Non–Small-Cell Lung Cancer
Questions and Answers: Small-Cell Lung Cancer
Irinotecan in Small-Cell Lung Cancer-Japanese Trials
Evolution of Combined Modality Therapy for Stage III Non–Small-Cell Lung Cancer
Phase I/II Trial of Irinotecan, Carboplatin, and Paclitaxel in Advanced or Metastatic NSCLC
Phase I/II Study of Weekly Irinotecan and Paclitaxel in Patients With SCLC
Weekly Irinotecan and Concurrent Radiation Therapy for Stage III Unresectable NSCLC
Extensive Small-Cell Lung Cancer: A Treatment Overview
Chemotherapy in Metastatic Non–Small-Cell Lung Cancer
Recent Videos
Patients with lung cancer who achieve a complete response with neoadjuvant therapy may not experience additional benefit with adjuvant immunotherapy.
Numerous trials have displayed the evolution of EGFR inhibition alone or with chemotherapy/radiation in the EGFR-mutated lung cancer space.
2 experts are featured in this series.
Although high grade adverse effects are infrequent among patients undergoing treatment for SCLC, CRS and ICANS may occur in higher frequencies.
Two experts are featured in this series.
Co-hosts Kristie L. Kahl and Andrew Svonavec highlight what to look forward to at the 67th Annual ASH Meeting in Orlando.
4 experts are featured in this series.
Based on a patient’s SCLC subtype, and Schlafen 11 status, patients will be randomly assigned to receive durvalumab alone or with a targeted therapy in the S2409 PRISM trial.
4 experts are featured in this series.
Daniel Peters, MD, aims to reduce the toxicity associated with AML treatments while also improving therapeutic outcomes.
Related Content
The intravesical MVR-T3911 treatment did not lead to any dose-limiting toxicities in patients with high-risk, BCG-unresponsive non-muscle invasive bladder cancer.

Novel Immunotherapy Achieves Responses/RFS in High-Risk, BCG-Unresponsive NMIBC

Tim Cortese
December 5th 2025
Article

The intravesical MVR-T3911 treatment did not lead to any dose-limiting toxicities in patients with high-risk, BCG-unresponsive non-muscle invasive bladder cancer.

Experts highlight considerations for treating patients with oligometastatic kidney cancer, such as differentiating between de novo and recurrent disease.

How to Manage Oligometastatic Kidney Cancer? Insights From IKCS 2025

Manojkumar Bupathi, MD, MS;Benjamin Garmezy, MD
December 4th 2025
Podcast

Experts highlight considerations for treating patients with oligometastatic kidney cancer, such as differentiating between de novo and recurrent disease.

Olverembatinib plus low-intensity chemotherapy achieved an MRD-negativity rate in about 65% of patients with newly diagnosed Ph+ ALL.

FDA and EMA Clear Phase 3 POLARIS-1 Trial in Newly Diagnosed Ph+ ALL

Tim Cortese
December 5th 2025
Article

Olverembatinib plus low-intensity chemotherapy achieved an MRD-negativity rate in about 65% of patients with newly diagnosed Ph+ ALL.

Experts from Georgia Cancer Center highlight ongoing retrospective studies, translational research, and other initiatives across different cancers.

Evolutions Across NSCLC, Multiple Myeloma, and AML at Georgia Cancer Center

Girindra Raval, MD;Amany Keruakous, MD;Daniel Peters, MD
December 1st 2025
Podcast

Experts from Georgia Cancer Center highlight ongoing retrospective studies, translational research, and other initiatives across different cancers.

Oncology care requires psychosocial support, nutrition, and survivorship, which can result in improved patient outcomes and quality of life.

Why Survivorship Matters: Creating Space in Multidisciplinary Cancer Care

ONCOLOGY Staff
December 5th 2025
Article

Oncology care requires psychosocial support, nutrition, and survivorship, which can result in improved patient outcomes and quality of life.

Treatment with liso-cel led to complete responses in 55.8% of patients with marginal zone lymphoma who received at least 2 prior lines of systemic therapy.

FDA Approves Liso-Cel in Marginal Zone Lymphoma After 2 Lines of Therapy

Tim Cortese
December 4th 2025
Article

Treatment with liso-cel led to complete responses in 55.8% of patients with marginal zone lymphoma who received at least 2 prior lines of systemic therapy.